Mario Alberto Accardi, Ph.D.
Chief Executive Officer and Co-Founder
Mario Alberto has a background in life sciences venture capital most recently gained at Fort Rock Capital, where as a Venture Partner he has led investments into a number of biotech, medtech and personalised medicine companies including vasopharm GmbH and GNS Healthcare. Previously he was with London based venture capital fund Entrepreneurs Fund and life sciences strategy firm Deallus Consulting. Mario holds a PhD in Biomedical Engineering from Imperial College London where his research focused on the pathogenesis of osteoarthritis and regenerative medicine. Mario also holds a First Class MEng degree in Mechanical Engineering and advanced studies in Genomic Medicine also from Imperial. He has a broad scientific background ranging from biomedical engineering, and regenerative medicine to genetics and molecular biology, and has published in several international peer reviewed scientific journals. Originally from Rome, Mario lives in London.
Dominique Kleyn, MBA
Chief Operating Officer and Co-Founder
Dominique previously spent 15 years in product and business development for Unilever, GSK and others before joining Imperial Innovations to mentor and incubate spin-out companies and then manage the life sciences technology transfer team. Latterly she headed up biotechnology and pharmaceutical corporate alliances for Imperial. She left Imperial in 2009 to join London Genetics as CEO and became CEO at Sierra MedTech in 2013. Dominique holds a BSc in Biology and MBA from Imperial.
Professor Andrew Amis, FREng
Technical Director and Co-Founder
Professor Amis is the Chair of Orthopaedic Biomechanics at Imperial College London as well as the Head of the Medical Engineering. He has 40 years of research in orthopaedic biomechanics, including the design of artificial human joints, tendons and ligaments and the mechanical analyses of biological systems and structures. He has over 300 peer-reviewed journal publications. In addition to research work, Andrew has acted as a consultant and expert witness for a number of areas of work, including implant design, failures of orthopaedic implants and industrial injuries.
Professor Justin Cobb, BM BCh MCh FRCS
Professor Cobb is the Chair in Orthopaedics at Imperial College London and is also the Founder of Acrobot, the worlds first haptic based robotic assistant. He is a Civilian advisor in orthopaedics to the Royal Air Force and is on the staff of King Edward VII hospital for Officers as well as being the Orthopaedic Surgeon to Her Majesty the Queen. Justin is a Graduate of Medicine at Magdalen College,Oxford. Justin’s research group is known to have secured £80m for the development of The Michael Uren Biomedical Engineering Hub which will enable engineers and medics to come together and develop new technologies.
Surbhi Gupta, Ph.D.
Surbhi joined Imperial Innovations in September 2015 and is responsible for commercializing opportunities arising from the Medtech area. Surbhi works predominantly with the Institute of Biomedical Engineering at Imperial College London. Prior to joining Imperial Innovations, Surbhi worked at King's College London and Cancer Research Technology (CRT) in similar roles leading on key revenue generating deals as well as spin-out company formation. Surbhi obtained her PhD in Biophysics from the Indian Institute of Science and followed this with post-doctoral research at the London Research Institute (LRI) where her work focused on understanding signalling pathways in tumour genesis.
Max Graziosi has worked for over 20 years in Capital Markets in a number of financial institutions in London including Credit Suisse, Bear Sterns and Nomura. He recently left Bank of America Merrill Lynch where he was a Managing Director, EMEA Chief Operating Officer for Fixed Income Currencies and Commodities. He has a vast experience in investing across many asset classes and industry sectors. He is an angel investor in a number of projects including The Kinase Project with Imperial Innovations Group plc, advancing LMTK3 as a therapeutic target for breast cancer and Maternal Matters Plc, a service providing social care to single mothers and their infants.